FONT-SIZE Plus   Neg

Command Security Names Paul Brost CFO - Quick Facts

Command Security Corp. (MOC) announced the appointment of Paul Brost as its Chief Financial Officer.Brost's appointment was effective immediately upon his employment start date of January 14, 2013, in conjunction with the opening of the Company's new corporate office.

Prior to joining the Company, Brost, age 59, served as the Vice President, Finance and Chief Financial Officer of UNISYS Federal Systems (UIS) from 2009 until 2010. In addition, from 2001 until 2009, he was the Senior Vice President, Finance for Orbital Sciences Corp. (ORB).

The company also announced that Barry Regenstein stepped down as Chief Financial Officer, effective upon Brost's appointment. At the same time, Regenstein agreed to remain with the Company in his role of President through the end of the company's current fiscal year, which ends March 31, 2013.

In addition, the company said it opened its new corporate headquarters in Herndon, VA which will consolidate headquarters personnel from three existing office locations. The transition of corporate functions is expected to be completed by February 15, 2013.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Visa Inc. (V) on Monday reported an increase in profit for the fourth quarter, as revenues jumped driven largely by increase in customer spending and inclusion of Europe business. Earnings and revenues trumped Wall Street expectations. Foster City, California-based Visa's fourth-quarter profit rose... As Sony Corp. prepares to launch the new PlayStation 4 Pro gaming console on November 10, several new games that are compatible with the console have also been confirmed for launch. Game developers are readying to provide PlayStation 4 Pro support for many games on PS4. Shares of Advaxis Inc. dropped more than 13 percent in pre-market activity before paring losses to just more than 5 percent after the company said that it was not able to complete the second stage of the Phase 2 GOG-0265 trial as designed due to a clinical hold that affected its clinical development programs last year.
comments powered by Disqus
Follow RTT